MRNA · Moderna IncHold

Moderna develops mRNA-based medicines and vaccines, most famously its COVID-19 vaccine.

why The headlines do not explain a ~570% rise for Moderna; the only relevant headline is a Merck (MRK) article that appears mislabeled, and no headline directly addresses a catalyst for such a dramatic move in MRNA.

Analysts are cautiously neutral — the explosive run has the street split, with more holds than buys suggesting people are watching from the sidelines.

AMD · Advanced Micro Devices IncBuy

Advanced Micro Devices designs computer processors and graphics chips used in PCs, data centers, and gaming consoles.

why AMD's stock likely rose as its CPU business gained ground on Intel while the company pursued AI chip ambitions, with one headline noting AMD's market cap now exceeds Intel's by ~60% after trailing badly a decade ago. source

Analysts are overwhelmingly bullish — the AI-driven chip boom has made this one of the market's favorite growth stories.

MRK · Merck & Co IncBuy

Merck is a global pharmaceutical company that makes prescription medicines, vaccines, and animal health products.

why Merck stock rose approximately 61% over the past year, with a headline directly confirming that gain and noting positive clinical trial results such as Phase 2b success for tulisokibart in hidradenitis suppurativa supporting investor confidence. source

Analysts lean strongly buy — the street sees durable momentum and a solid drug pipeline backing up the big gain.

GOOGL · Alphabet IncBuy

Alphabet runs Google Search, YouTube, and a major cloud computing business, making most of its money from digital advertising.

why Alphabet's stock likely rose in part because it prevailed in two US antitrust lawsuits, removing a significant legal overhang for the company. source

Analysts are firmly bullish — strong buy consensus suggests confidence in its AI positioning and ad revenue engine.

LLY · Eli Lilly and CoBuy

Eli Lilly makes pharmaceutical drugs, with its blockbuster weight-loss and diabetes medicines driving enormous recent interest.

why Eli Lilly's stock rose on strong growth prospects, including positive late-stage diabetes study results for Foundayo and an FDA-expanded indication for its cancer drug Jaypirca, reinforcing its pipeline strength. source

Analysts are broadly bullish — the GLP-1 drug wave has the street very excited, though a recent pullback has some watching closely.

JNJ · Johnson & JohnsonBuy

Johnson and Johnson is a healthcare giant producing pharmaceuticals, medical devices, and consumer health products.

why The provided headlines do not clearly explain a ~38% rise in Johnson & Johnson stock; the most relevant headline mentions sustained Phase 3 skin clearance results for ICOTYDE but does not directly attribute it to the overall annual gain. source

Analysts lean buy — seen as a steady, reliable compounder with solid fundamentals backing the strong yearly gain.

AAPL · Apple IncBuy

Apple designs and sells iPhones, Macs, iPads, and a growing suite of software and subscription services.

why Apple posted the best performance among the Magnificent Seven in September and exceeded broader market returns, driven in part by its push into AI agents, contributing to its ~30% annual gain. source

Analysts are bullish overall — the world's most valuable company still commands strong confidence despite the lofty valuation.

NVDA · NVIDIA CorpBuy

NVIDIA makes graphics processing units that power AI model training, data centers, gaming, and autonomous vehicles.

why The provided headlines do not directly explain Nvidia's ~24% annual price change; none of the listed articles focus specifically on Nvidia's business performance or catalysts driving its stock over the past year.

Analysts are almost unanimously bullish — widely regarded as the backbone of the AI infrastructure buildout.

TMO · Thermo Fisher Scientific IncBuy

Thermo Fisher Scientific supplies instruments, reagents, and services to laboratories, hospitals, and drug manufacturers worldwide.

why The provided headlines do not clearly explain Thermo Fisher's ~25% annual gain; the articles mention Thermo Fisher only in the context of broad market reports on bio-manufacturing and biomarker growth, without pinpointing a specific stock catalyst.

Analysts are solidly bullish — viewed as a high-quality, defensive growth business with broad demand across science and healthcare.

ABBV · AbbVie IncBuy

AbbVie is a biopharmaceutical company best known for its immune-disease drug Humira, while building out a newer drug portfolio.

why AbbVie's stock was supported by the FDA approval of a once-daily Parkinson's pill, adding a new product to its portfolio and reinforcing its pipeline strength. source

Analysts lean buy — the street sees the post-Humira transition holding up well, with pipeline drugs picking up the slack.

ORCL · Oracle CorpBuy

Oracle sells database software, cloud infrastructure services, and enterprise applications to businesses globally.

why The headlines do not provide a clear explanation for Oracle's ~51% price decline over the past year; the most relevant headline references Larry Ellison's risk exposure tied to Oracle's debt binge, which could have weighed on investor sentiment, but the sources do not directly explain the full magnitude of the drop. source

Analysts still lean buy despite the steep drop — the consensus suggests this is seen as an overreaction with recovery potential, though the fall is hard to ignore.

COIN · Coinbase Global IncBuy

Coinbase operates a platform where individuals and institutions can buy, sell, and store cryptocurrencies.

why The provided headlines do not directly explain Coinbase's ~45% price decline over the past year; they reference crypto market weakness and Bitcoin hitting a bottom, but no headline clearly accounts for the stock's specific decline.

Analysts are net bullish but cautious — crypto volatility makes this a high-conviction bet for some and a hard pass for others.

MSFT · Microsoft CorpBuy

Microsoft makes the Windows operating system, Office productivity software, Azure cloud services, and owns LinkedIn and Xbox.

why The provided headlines do not explain Microsoft's near-flat (~0.3%) performance over the past year; they include general market commentary and speculation about a stock split but nothing that explains the price movement.

Analysts are overwhelmingly bullish — the near-flat year is seen as a pause, not a problem, with AI tailwinds firmly in view.

META · Meta Platforms IncBuy

Meta Platforms owns Facebook, Instagram, and WhatsApp, generating revenue primarily through targeted digital advertising.

why Meta's stock was roughly flat over the past year despite positive narratives around Mark Zuckerberg's strategy and AI investment, with one headline noting that Zuckerberg is 'winning for investors again,' suggesting gains were offset by broader market pressures. source

Analysts are strongly bullish — the ad business is firing on all cylinders and most on the street see continued upside ahead.

BRK.B · Berkshire Hathaway IncSell

Berkshire Hathaway is Warren Buffett's conglomerate that owns a wide range of businesses from insurance to railroads to consumer brands.

why The provided headlines do not clearly explain Berkshire Hathaway's near-flat (~0.8%) performance; headlines discuss Warren Buffett stepping back as chairman and Greg Abel's new era, which may have introduced uncertainty, but no single headline directly explains the price movement. source

Analysts are notably cautious — one of the few large-caps with a sell-leaning consensus, reflecting limited near-term upside at current prices.

PFE · Pfizer IncHold

Pfizer is a global pharmaceutical company known for a broad drug portfolio and its COVID-19 vaccine and antiviral pill.

why The provided headlines do not clearly explain Pfizer's modest ~2.7% gain; headlines reference positive clinical trial results for LITFULO (ritlecitinib) in vitiligo and eczema, which may have provided some upside, but the sources do not fully account for the annual price movement. source

Analysts are neutral — the street is in wait-and-see mode as Pfizer works through a post-COVID revenue hangover and rebuilds its pipeline.

AVGO · Broadcom IncBuy

Broadcom designs semiconductors and software used in networking, broadband, storage, and wireless communications.

why The provided headlines do not clearly explain Broadcom's modest ~5% gain; one headline references Broadcom extending a $42 billion loan to Anthropic, positioning the chipmaker as a financial partner to AI customers, which may reflect its growing AI ecosystem role, but the sources do not fully explain the annual price move. source

Analysts are strongly bullish — AI networking demand and a diversified chip portfolio keep the street firmly in the buy camp.

UNH · UnitedHealth Group IncBuy

UnitedHealth Group is the largest US health insurer, also running a large pharmacy and healthcare services division called Optum.

why UnitedHealth's modest ~5% gain over the past year was likely pressured by the company cutting Medicare Advantage plans and shutting coverage for approximately 390,000 Medicare Advantage members, signaling cost-control challenges heading into 2027. source

Analysts lean buy — recent turbulence has rattled sentiment but most see the underlying business as fundamentally sound.